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Abstract: Restless leg syndrome (RLS) disrupts sleep, affecting the quality of life of patients with
various chronic diseases. We assessed the prevalence of RLS in peripheral artery disease (PAD) patients
and the effects of a pain-free exercise program. A total of 286 patients with claudication were enrolled
in a home-based low-intensity exercise program prescribed at the hospital. RLS was determined
through standardized questions. Hemodynamics, degree of calf deoxygenation, and mobility were
assessed using the ankle-brachial-index, a treadmill test assisted by near-infrared spectroscopy and
the 6-min walk test, respectively. During hospital visits, persistence of RLS, adherence to exercise,
hemodynamics, and mobility were assessed. At the enrollment, 101 patients (35%) presented RLS,
with higher prevalence among females (p = 0.032). Compared to RLS-free patients, they showed
similar hemodynamics but more severe calf deoxygenation (p < 0.001) and lower mobility (p = 0.040).
Eighty-seven RLS patients (83%) reported the disappearance of symptoms after 39 (36−70) days
of exercise. This subgroup, compared to nonresponders, showed higher adherence (p < 0.001),
hemodynamic (p = 0.041), and mobility improvements (p = 0.003). RLS symptoms were frequent
in PAD but were reduced by a pain-free walking exercise aimed at inducing peripheral aerobic
adaptations. The concomitant recovery of sleep and mobility may represent a synergistic action
against the cardiovascular risk in PAD.
Keywords: peripheral artery disease; restless leg syndrome; exercise therapy; rehabilitation;
spectroscopy; near-infrared
1. Introduction
Restless legs syndrome (RLS), a common sensory-motor disorder with a relatively high prevalence
in older people and females, causes unpleasant sensations in patients’ limbs and induces patients to
move their legs [1–4]. Interestingly, RLS symptoms exhibit a distinct circadian pattern, with an increase
in both sensory and motor symptoms in the evening and at night [5]. On the one hand, immobility
plays an important role, and a worsening of RLS symptoms by nocturnal immobility is closely linked
to intrinsic circadian variations [6]. On the other hand, periodic limb movements during sleep show a
nocturnal pattern, with most of the movements peaking at the beginning of the night, preceding the
evening melatonin rise [7]. The sleep disruptions that occur may be responsible for daytime sleepiness,
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fatigue [1,8,9], and impaired performance during activities of daily living [10]. Finally, an association
between RLS and a high risk of suicide and self-harm, independent of comorbidities and conditions,
has been recently reported [11].
To improve the detection of RLS, clinical diagnostic criteria have been established and reviewed [12].
Unfortunately, the effects of the disorder remain underestimated by patients and poorly reported to
their doctors [1,2]. In addition to the primary idiopathic form, RLS has been associated with specific
conditions (peripheral hypoxia [13], iron deficiency [14], and pregnancy) and several chronic diseases,
including neurological diseases, diabetes, cardio-cerebrovascular diseases, or with the presence of
more medical comorbidities [5,15–17]. In some cases, the symptoms are associated with significant
decrements in health-related quality of life and clinical outcomes [2,16,18,19], and the patients may
benefit from various pharmacological agents, as well as moderate-intensity exercise [2,18,20–23].
Because the pathogenesis of RLS may result from an uncoupling between central inhibition and
peripheral nerve function, vascular factors such as endothelial dysfunction, changes in the peripheral
microvasculature and peripheral hypoxia have been recently studied [3].
Therefore, RLS might represent a poorly estimated problem [24] in patients with peripheral
artery disease (PAD), a pathology that is highly prevalent in elderly people and end-stage renal
disease patients [25] and characterized by a reduction in the amount of oxygen delivered to the
working muscles [26]. Nocturnal extravascular symptoms in PAD patients might be responsible for
sleep disruption, which increases the risk for cardiovascular disease and sedentary behavior in these
patients [27,28]. Unfortunately, few studies on this topic are available.
The aims of this retrospective study were to assess the frequency of RLS in a PAD population
enrolled in a rehabilitation program and to describe the effects of a low-intensity, pain-free exercise
program properly developed for PAD patients [29,30] and adapted for frail individuals [31–34].
We hypothesized that rehabilitation and this type of exercise in particular, due to its favorable
muscular and vascular effects [35,36], might improve RLS symptoms in affected patients.
2. Materials and Methods
2.1. Subjects and Settings
This single-center study retrospectively analyzed a prospectively collected database of 286 PAD
patients enrolled between 2015 and 2018 in the Vascular Rehabilitation Program at the University
Hospital of Ferrara. Patients were previously screened through a Doppler ultrasound examination at
the department of vascular surgery to assess the presence and severity of PAD.
The local ethics committee approved the study, and the tests conducted in this study were a part
of the usual care for PAD patients at the University Hospital of Ferrara.
2.2. Variables Assessed upon Enrollment
Upon enrollment in the program, information regarding the clinical status and functional
impairment of the patients were collected by consulting patients’ medical documents or conducting
specific tests and questionnaires.
In particular, anthropometric data (age, sex, and weight), educational levels, cardiovascular
risk factors, the use of medications, comorbidities identified through the Charlson Comorbidity
Index [37], the location and severity of endovascular lesions, and patients’ reported claudication
distance were noted.
In addition, the presence of RLS was determined by the same physician according to the four
criteria highlighted by the European Restless Legs Syndrome Study Group (EURLSSG) guidelines [1].
Specifically, if at least one positive answer was obtained, adjunctive questions from the RLS-diagnostic
index were posed to diagnose RLS. The patients were then divided into RLS+ and RLS− groups
depending on the presence of RLS at baseline.
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2.3. Outcome Measures
A battery of hemodynamic and functional tests were performed on the same day between 8:30
and 12:30 a.m. in a temperature-controlled environment to determine the hemodynamic severity, the
individual degree of muscle deoxygenation occurring while walking, and the functional capacity of
each patient.
Hemodynamic assessment: After five minutes of rest, the ankle-brachial index (ABI) was measured
according to the standard procedure [38] by a Doppler ultrasound (Stereodop 448. S; Ultrasomed,
Milan, Italy) on both limbs. The leg with the lower ABI value was considered the more impaired leg.
The vessels were considered “not compressible” for ABI measurements >1.31.
Degree of muscular oxygenation: After a suitable duration of rest, the degree of muscular
oxygenation was determined by means of an incremental treadmill test [39] assisted by near-infrared
spectroscopy (NIRS) [40]. NIRS sensors were attached to each patient’s medial gastrocnemius muscle.
The NIRS system (Oxymon MK III Artinis Medical System, the Netherlands) comprised of 2 channels
(2 pulsed light sources and 2 detectors) that emitted infrared light at a frequency of 1 Hz. The intensity
of the reflected light provided information about oxygenated hemoglobin (oxy-Hb) concentration.
For the treadmill test, patients walked on level ground at a slow initial speed (1.5 km/h), and
small increases to the speed were made (0.1 km/h every 10 m) until the maximal speed (Smax) or a
speed that a patient was unable to maintain for any reason (peripheral symptoms, fatigue, or dyspnea)
was reached.
During the test, the speed at the onset of claudication symptoms or the pain threshold speed (PTS)
was also recorded. At the end of the sessions, NIRS data were analyzed with dedicated software to
determine the maximal degree of deoxygenation (or the most negative values reached during the test)
and the area under the curve of the oxy-Hb concentration [40].
Functional measurement: The 6-min walk test was performed to assess exercise capacity [41].
Patients were asked to walk back and forth on a 20-m corridor for a total duration of 6 min and to
cover as much distance as possible in the fixed duration. During the test, the patients were asked to
indicate when the onset of claudication symptoms occurred, and they were allowed to stop whenever
they needed for leg symptoms or fatigue. The same skilled assessor recorded the total distance
walked (6-min walking distance, 6MWD) and the distance at the onset of symptoms (pain-free walking
distance) for all patients.
2.4. Exercise Program
All patients received the ‘Test in–Train out’ (Ti-To) structured home-based exercise program [29,30],
composed of a hospital-based phase and a home-based phase with walking exercises. The hospital-based
phase included approximately monthly visits at the hospital for clinical evaluations, including an
assessment of RLS presence, ABI and 6MWD measurements, an updated prescription of the home-based
program, and an evaluation of the patient’s adherence to the home-based program.
The home-based phase included the execution of exercises at home, preferably indoors. The
program was based on two 10-min walking sessions per day (six days per week) of intermittent walking
(one minute of walking and one minute of resting while seated) at a prescribed speed; in the beginning,
the prescribed speed was slower than the patient’s typical walking speed, and then the prescribed
speed increased weekly. The training speed was converted into a walking cadence (steps/minute) that
was to be maintained at home with a metronome. The patients were specifically instructed to walk in
rhythm with the metronome. Training progression included both speed increases from 60 to 84–100
steps/min according to the severity of claudication and walk–rest ratio increases from 1:1 to 2:1 and 3:1.
Patients were asked to fill out a daily training record indicating completion of the exercises, any
related symptoms, and the presence or absence of RLS or cramps each night.
Patients were discharged from the program when they were satisfied with the improvements in
pain-free walking distance (PFWD); for example, a patient was discharged when he or she reached a
symptom-free walking speed that was normal for his or her age or when claudication symptoms were
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stable for three consecutive tests. The percentage of completed exercise sessions with respect to the
prescribed number of sessions was calculated at the end of the program.
2.5. RLS Progression throughout the Program
Patients who experienced RLS at baseline were asked about RLS remission or persistence at each
hospital visit. If RLS remission was reported, the number of days since the beginning of the program
was calculated.
2.6. Statistical Analysis
Continuous data are expressed as the mean± standard deviation and categorical data are expressed
as number and percentage.
RLS+ and RLS− group comparisons were performed by independent t-tests (normally distributed
data), Mann–Whitney tests (nonnormally distributed data), or chi-squared tests (categorical data), as
appropriate. Multiple and logistic regression models with a stepwise selection method were applied to
identify factors related to RLS remission after the exercise program. Independent variables considered
at baseline were: age, sex, BMI, risk factors and comorbidities (Table 1), disease duration and severity
(ABI), Smax, PFWD and 6MWD, and deoxygenation at calves. In addition, for logistic regression an
improvement of PFWD and 6MWD arbitrarily set at 25 m and an ABI improvement greater than 0.05
for both limbs were also considered.
Table 1. Characteristics of the population included in the study.
Whole Population (n = 286)
Age, years 71 ± 9
Males, n (%) 219 (77)
BMI (kg·m−2) 28 ± 5





Familiarity for CVD 26 (9)
Comorbidities, n (%)
Coronary artery disease 111 (39)
Lung disease 49 (17)
Osteoarticular disorders 71 (25)
Chronic kidney disease 51 (18)
Cerebrovascular disease 29 (10)
Lower limbs revascularizations 78 (27)







Hypoglycemic agents and/or insulin 138 (48)
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Table 1. Cont.
Whole Population (n = 286)
Gabapentin 2 (0.01)
Peripheral artery disease
Duration, years 4 ± 7
ABI more diseased limb 0.68 ± 0.21
ABI less diseases limb 0.84 ± 0.19
Speed at symptoms (km·h−1) 2.7 ± 0.9
Maximal speed (km·h−1) 3.3 ± 1.0
Pain-free walking distance (m) 142 ± 83
6-min walking distance (m) 313 ± 81
Abbreviations: ABI, ankle-brachial index.
Within-group comparisons concerning RLS remission or persistence were assessed by paired t-tests
(normally distributed data) or Wilcoxon rank tests (nonnormally distributed data), as appropriate. The
between-group comparisons of outcome variations obtained at the end of the program were performed
with one-way analysis of variance.
A p-value of <0.05 was considered statistically significant. All statistical analyses were performed
using MedCalc Statistical Software version 19.0.3 (MedCalc Software bvba, Ostend, Belgium). Research
data are available at http://dx.doi.org/10.17632/j4dhkwmw3n.1
3. Results
A total of 286 patients were evaluated upon enrollment in the rehabilitation program. The
characteristics of the population, including anthropometric measures, comorbidities, medications, and
PAD-related data, are reported in Table 1.
3.1. RLS Prevalence
Upon enrollment, 101 patients (35%) reported having RLS by providing positive answers to the
questionnaire. All of the patients presented with nighttime symptoms, and the majority of the patients
had intermittent RLS (n = 90). Fourteen patients were already treated with a drug suggested by
EURLSSG, but they still reported symptoms (Table 1).
At baseline, a higher prevalence of RLS was observed in females than in males (p = 0.032), and
patients in the RLS+ group showed a lower exercise capacity, measured both on the treadmill and over
ground, than the RLS− group did. The comparison between the two groups is reported in Table 2.
Table 2. Characteristics of the population included in the study.
RLS+ (n = 101) RLS− (n = 185) p
Age, years 71 ± 9 72 ± 9 0.51
Males, n (%) 70 (69) 149 (81) 0.032
BMI (kg·m−2) 28 ± 5 27 ± 5 0.76
Risk factors, n (%)
Smoking 82 (81) 157 (85) 0.42
Hypertension 74 (73) 141 (76) 0.58
Dyslipidemia 74 (73) 141 (76) 0.58
Diabetes 52 (52) 86 (47) 0.42
Familiarity for CVD 8 (8) 18 (10) 0.61
Comorbidities, n (%)
Coronary artery disease 36 (36) 75 (41) 0.42
Lung disease 17 (17) 32 (17) 0.88
Osteoarticular disorders 23 (23) 48 (26) 0.55
Chronic kidney disease 24 (24) 27 (15) 0.06
Cerebrovascular disease 10 (10) 19 (10) 0.79
Lower limbs revascularizations 32 (32) 46 (25) 0.21
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Table 2. Cont.
RLS+ (n = 101) RLS− (n = 185) p
Charlson Index 6.4 ± 2.0 6.2 ± 2.0 0.41
Therapy, n (%)
Anticoagulants 10 (10) 22 (11) 0.67
Antiplatelet 90 (89) 171 (92) 0.55
Anti-hypertensive 74 (73) 141 (76) 0.58
Diuretics 38 (38) 52 (28) 0.10
Statins 74 (73) 141 (76) 0.58
Hypoglycemic agents and/or insulin 52 (52) 86 (47) 0.42
RLS-treatment drugs 14 (14) 4 (2) <0.001
Peripheral artery disease
Duration, years 4 ± 4 4 ± 7 0.81
ABI more diseased limb 0.69 ± 0.22 0.68 ± 0.20 0.83
ABI less diseases limb 0.83 ± 0.19 0.84 ± 0.20 0.77
Speed at symptoms (km·h−1) 2.5 ± 0.8 2.8 ± 1.0 0.018
Maximal speed (km·h−1) 3.1 ± 1.0 3.4 ± 1.0 0.032
Pain-free walking distance (m) 132 ± 90 148 ± 70 0.12
6-min walking distance (m) 300 ± 75 320 ± 84 0.044
Abbreviations: ABI, ankle-brachial index.
In addition, compared to the RLS− group, the RLS+ group showed a significantly higher degree
of deoxygenation in both the more impaired limb (−14.1 ± 7.0 arbitrary units (a.u.) for RLS+ versus
−7.6 ± 4.6 a.u. for RLS−; p < 0.001) and the less impaired limb (−8.2 ± 4.8 a.u. for RLS+ versus −3.8 ±
3.6 a.u. for RLS−; p < 0.001).
No differences were observed in the area under the curve of the oxygenated hemoglobin in both
limbs due to a longer duration of the test observed in the RLS− group than in the RLS+ group. The
data are represented in Figure 1.
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3.2. RLS after the Exercise Program
All patients completed the prescribed exercise program without any adverse events. Within the
RLS+ group, 83 patients (82%) reported the disappearance of RLS during the program, while the
remaining 18 (18%) did not. RLS remission occurred after a median of 39 days of training (interquartile
range: 36–70), corresponding to the time of the first hospital visit after the beginning of the program.
Among the 14 patients who were taking medications for RLS, 13 reported a remission of symptoms
after a median of 39 days, while one patient had a persistence of RLS until the end of the program.
Compared with the remaining patients, the subgroup who exhibited RLS remission executed a
significantly higher number of exercise sessions, showed greater hemodynamic improvements in the
more impaired limb (and significantly larger changes in the PFWD and 6MWD (Table 3).
Table 3. Outcomes of the exercise program within restless leg syndrome (RLS)+ group of patients who
either did or did not exhibit RLS remission.
RLS Remission (n = 83) RLS Persistence (n = 18) p
Program duration (days) 288 ± 121 304 ± 117 0.23
Exercise sessions executed (%) 94 71 <0.001
∆ ABI more diseased limb 0.05 ± 0.11 0.00 ± 0.12 0.041
∆ ABI less diseases limb 0.03 ± 0.14 0.02 ± 0.12 0.43
∆ Pain-free walking distance (m) 82 ± 79 40 ± 88 0.049
∆ 6-min walking distance (m) 20 ± 43 −11 ± 32 0.003
Abbreviations: ABI, ankle-brachial index.
Within the statistically significant logistic regression model (R2 0.10; p = 0.011), the only factor
related to the remission of RLS was an increase in the 6MWD greater than 25 m (Odds ratio: 8.00; 95%
confidence interval 1.01 to 63.56).
4. Discussion
The study revealed a high percentage of PAD patients with claudication suffering from RLS and
nocturnal muscular cramps. Among these patients, the presence of nocturnal symptoms was related to
low mobility and a high degree of calf deoxygenation while walking during an incremental treadmill
test assisted by NIRS. The study also showed that low-intensity pain-free walking exercise was able
to reverse the symptoms in a large percentage of the patients enrolled in a structured home-based
rehabilitation program [29,30].
The prevalence of nocturnal RLS symptoms has been poorly described in PAD patients. In the
general population, according to the analysis derived from three prospective studies, a decreased ABI
was not found to be a risk factor for RLS [42]. However, patients with PAD often present comorbidities
associated with RLS such as chronic kidney disease (CKD). Among dialysis patients, who often have
PAD [2,43], RLS and muscle cramps were reported in 16% to 30% of the patients studied [2,43–45],
and there was no association between PAD and cramps during dialysis [43,44]. The symptoms that
were reported had an age-dependent prevalence [44], and symptoms were reported more frequently in
women than in men among dialysis and nondialysis CKD patients [18,45]. RLS was also found to have
a variable prevalence (7–24%) in diabetic patients, with poor sleep quality [46–49], and with nocturnal
symptoms; in some cases, RLS was associated with peripheral neuropathy [46].
However, the prevalence of RLS is strongly dependent on the method of assessment: the use
of standardized questionnaires only or additional neurological examinations. When a neurological
examination or a diagnostic questionnaire which removes RLS mimics were associated to the pool of
questions, the prevalence of RLS dropped from 21% to 4.5% among dialysis patients and from 22% to
8% in patients with peripheral neuropathy [18,50].
In the study population of PAD patients, the prevalence of RLS that was determined by the
four questions was high (35%). This prevalence, considering the low number of patients under
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pharmacological treatment, suggests that RLS is poorly estimated or treated in these patients. The
prevalence was significantly higher in females than in males, but there were no differences in prevalence
with different levels of BMI, with the use of diuretics, with the presence of comorbidities, with different
durations of the disease or with different ABI values. In this population, the mobility at baseline
measured by a validated test was inversely correlated with the presence of nocturnal symptoms. A
relationship between the physical activity level assessed by questionnaires or other health-related
quality of life (HRQoL) measures and the perception of physical limitations and pain was also observed
in other patients with RLS [8]. Interestingly, among diabetic patients with RLS, a higher physical
activity level was associated with better HRQoL measures, less pain, and physical limitations. [8].
Our study supports the previous findings of Salminen et al. [13] who noninvasively measured the
peripheral oxygen partial pressures on the skin of the legs observing an association between peripheral
hypoxia and appearance of RLS symptoms. Moreover, the present study adds an additional element of
discussion, because of the beneficial use of the NIRS technique, which allowed a dynamic noninvasive
study of muscle metabolism inside the tissue and not only on the skin and during a standardized
walking task and not only at rest [40]. This technique revealed that patients with a high degree of
muscle deoxygenation in both limbs while walking rather than those that had more severe PAD were
suffering more from RLS. This observation is interesting for different reasons. The first reason is that
the presence of a new objective parameter correlated with the symptoms. According to some authors,
the lack of objective diagnostic findings (e.g., neurological tests) may be attributed to the psychogenic
origin of these symptoms [27]. Second, NIRS—unlike a static measure of hemodynamic delivery such
as ABI—explores the dynamic imbalance between oxygen request and both delivery and utilization in
the muscles.
This analysis more closely describes the aerobic inefficiency of muscles (collaterals, capillaries,
microcirculation, and mitochondrial activity) [51] that is potentially associated with chronic peripheral
fatigue. Among the multiple mechanisms that contribute to the pathogenesis of RLS, metabolic factors
(hypoxia and muscle fatigue) may affect peripheral nerve function and alter both central and especially
peripheral excitability in individuals with RLS [19]. Interestingly, performing physical activity just
before going to bed has been linked to an increase in RLS symptoms [8,52]. Other factors involved in
oxygen delivery have also been associated with RLS, such as poor vascular endothelial function [3],
altered brachial arterial pulse wave velocity in patients with acute ischemic stroke [16] or greater
peripheral vascular resistance [53]. Conversely, the administration of drugs with vasodilating effects
such as cilostazol partially improved the clinical symptoms of RLS [25]. Finally, low iron and ferritin
concentrations, conditions potentially associated with anemia and reduced oxygen transport, have
also been considered factors that trigger RLS [14].
Finally, the study supports the role of exercise in managing these nocturnal symptoms. In dialysis
patients, in addition to medications (dopamine agonists, benzodiazepines, antiepileptics, iron, and
vitamins), exercise, particularly aerobic exercise, reduced RLS symptoms in CKD patients [54–56].
Improvements in insomnia and RLS symptoms and HRQoL were also reported after exercise in
hemodialysis patients [2,21–23,57,58]. Aerobic exercise could reduce RLS symptoms [9,12,23,55,59] by
evoking favorable adaptations in aging skeletal muscles [60], increasing endorphin production [61–63],
improving thermoregulation, which favors sleep [2,57], or inducing vasodilation with improvements
in blood supply [2,64].
In our study, the RLS symptoms were significantly and rapidly reduced after many repetitions of
the same type of low-intensity exercise, which previously induced peripheral hemodynamic and muscle
aerobic adaptations, as highlighted by the NIRS technique, in PAD and in dialysis patients [35,36]. This
intervention potentially has a summation effect on pharmacological therapy, considering that almost
all patients that were taking the prescribed RLS drugs showed partial benefits from the drugs reported
remission of their symptoms after a few weeks of training.
The reduction in symptoms observed with rehabilitation represents the removal of an additional
cardiovascular risk factor in a population at high risk for cardiovascular disease. An overactivity of the
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nocturnal HPA system, characterized by significantly enhanced nocturnal cortisol excretion, has been
shown in RLS subjects. Such hyperactivity has been considered a possible mechanism contributing to
the increased prevalence of cardiovascular disease in RLS patients than in control subjects [65]. In fact,
patients with RLS have been shown to show higher nocturnal and sleep-time systolic blood pressure
compared to control subjects with no sleep disorders [66]. Moreover, hypertension and RLS symptoms
seem to be linked since patients with nondipping blood pressure patterns (NDBPP) had higher RLS
symptom scores and more severe RLS symptoms than patients who had RLS but not NDBPP [67]. Sleep
fragmentation and deprivation altered circadian rhythms with proinflammatory and proatherosclerotic
effects [27,68]. As a consequence, mood disturbance and loss of performance due to sleep disruption
may negatively affect the willingness and capacity to exercise during rehabilitation [2].
In addition to the strengths of our study, which include the large sample size and novel use of NIRS
technology for improving scientific knowledge, a number of limitations remain in this retrospective
study, without a control group. RLS was assessed by a few questions, during a face-to-face interview,
without confirmation by diagnostic tests or the involvement of sleep specialists. This limitation is
relevant because nocturnal leg cramps are common in older people and are associated with many
common diseases and medications [20]. Moreover, in addition to the diagnostic procedure, the presence
of chronic pain or population differences may have affected the results of the study [50]. Finally, nor
the family history of RLS or the presence of periodic limb movements, nor the RLS severity were
evaluated. RLS was also not correlated to the degree of PAD, and secondary RLS related to CKD and
iron deficiency anemia were not assessed.
5. Conclusions
The prevalence of RLS as assessed by a standardized number of questions was high in a PAD
population with claudication. The symptoms were not related to disease severity measured at rest
but were related to the degree of metabolic fatigue in muscles assessed during treadmill walking.
The remission of nocturnal symptoms in several patients by the execution of low-intensity exercise
supports the effectiveness of this intervention, at least in the presence of a muscle-altered metabolic
status. However, this preliminary observation needs to be confirmed in prospective studies with
neurological evaluations.
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